Q2 2025 Earnings Estimate for Pacira BioSciences, Inc. Issued By Zacks Research (NASDAQ:PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research decreased their Q2 2025 EPS estimates for Pacira BioSciences in a research note issued on Friday, April 26th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.66 per share for the quarter, down from their previous estimate of $0.67. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.18 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.80 EPS and Q1 2026 earnings at $0.72 EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush reissued an “outperform” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a report on Thursday, February 8th. JPMorgan Chase & Co. began coverage on shares of Pacira BioSciences in a report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective for the company. TheStreet raised shares of Pacira BioSciences from a “d+” rating to a “c” rating in a report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and issued a $45.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a report on Monday, March 4th. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pacira BioSciences has an average rating of “Buy” and an average price target of $49.50.

Pacira BioSciences Trading Up 3.3 %

Shares of PCRX opened at $26.33 on Monday. The company has a current ratio of 5.24, a quick ratio of 4.17 and a debt-to-equity ratio of 0.59. Pacira BioSciences has a 12-month low of $25.33 and a 12-month high of $48.60. The firm has a 50-day moving average price of $28.71 and a 200 day moving average price of $29.63. The firm has a market capitalization of $1.22 billion, a P/E ratio of 32.51 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The company had revenue of $181.24 million during the quarter, compared to analyst estimates of $180.60 million.

Insider Buying and Selling at Pacira BioSciences

In other news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the sale, the director now owns 22,127 shares of the company’s stock, valued at $677,086.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Gary W. Pace sold 1,066 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Gary W. Pace sold 90,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares in the company, valued at approximately $677,086.20. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Pacira BioSciences

Several hedge funds have recently added to or reduced their stakes in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 9.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company’s stock valued at $157,000 after acquiring an additional 438 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 96.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock valued at $36,000 after acquiring an additional 583 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC raised its holdings in Pacira BioSciences by 5.6% in the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 11,185 shares of the company’s stock valued at $343,000 after acquiring an additional 590 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in Pacira BioSciences by 2.2% in the fourth quarter. Illinois Municipal Retirement Fund now owns 26,964 shares of the company’s stock valued at $910,000 after acquiring an additional 591 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Pacira BioSciences by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 13,064 shares of the company’s stock valued at $401,000 after acquiring an additional 597 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.